Three insights:
1. The rebranding reflects the company’s work with fibroblasts, which includes cell therapy treatments for chronic diseases and the development of a potential cure for degenerative disc disease.
2. The company has 180 issued and pending patents in a variety of areas, including disc degeneration, multiple sclerosis and Parkinson’s.
3. FibroGenesis, completely funded by angel investors, will be wholly owned by SpinalCyte.
More articles on devices:
Bundled payments in spine: 12 key thoughts for 2020
Breaking down the 3 major robots in spine surgery
8 spine, neurosurgeon moves
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
